KR20180034589A - 면역 반응을 유도하기 위한 신규한 방법 - Google Patents

면역 반응을 유도하기 위한 신규한 방법 Download PDF

Info

Publication number
KR20180034589A
KR20180034589A KR1020187005661A KR20187005661A KR20180034589A KR 20180034589 A KR20180034589 A KR 20180034589A KR 1020187005661 A KR1020187005661 A KR 1020187005661A KR 20187005661 A KR20187005661 A KR 20187005661A KR 20180034589 A KR20180034589 A KR 20180034589A
Authority
KR
South Korea
Prior art keywords
polypeptide
adenovirus
antigen
related antigen
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187005661A
Other languages
English (en)
Korean (ko)
Inventor
마리에-앙쥬 데모이티에
마리에-노일레 도너
나디아 오크드
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20180034589A publication Critical patent/KR20180034589A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187005661A 2015-07-27 2016-07-25 면역 반응을 유도하기 위한 신규한 방법 Withdrawn KR20180034589A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1513176.6A GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response
GB1513176.6 2015-07-27
PCT/EP2016/067622 WO2017017050A1 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
KR20180034589A true KR20180034589A (ko) 2018-04-04

Family

ID=54106649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005661A Withdrawn KR20180034589A (ko) 2015-07-27 2016-07-25 면역 반응을 유도하기 위한 신규한 방법

Country Status (15)

Country Link
US (4) US20180216081A1 (cg-RX-API-DMAC7.html)
EP (2) EP3328420A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018521666A (cg-RX-API-DMAC7.html)
KR (1) KR20180034589A (cg-RX-API-DMAC7.html)
CN (2) CN108135991A (cg-RX-API-DMAC7.html)
AR (1) AR105470A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016301029B2 (cg-RX-API-DMAC7.html)
BE (2) BE1023916A9 (cg-RX-API-DMAC7.html)
BR (2) BR112018001572A2 (cg-RX-API-DMAC7.html)
CA (2) CA2993371A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890355A1 (cg-RX-API-DMAC7.html)
GB (1) GB201513176D0 (cg-RX-API-DMAC7.html)
IL (1) IL257071A (cg-RX-API-DMAC7.html)
MX (2) MX2018001215A (cg-RX-API-DMAC7.html)
WO (2) WO2017017049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
DK3436591T5 (da) * 2016-03-31 2024-09-16 The European Molecular Biology Laboratory Adenovirale coat-protein-afledte transportvehikler
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3697919A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals SA Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
CN111479926A (zh) * 2017-10-16 2020-07-31 葛兰素史密丝克莱恩生物有限公司 具有两个表达盒的猿猴腺病毒载体
CN111655847A (zh) * 2017-10-16 2020-09-11 葛兰素史密丝克莱恩生物有限公司 能够复制的腺病毒载体
BR112020007042A2 (pt) * 2017-10-16 2020-11-17 Glaxosmithkline Biologicals S.A. promotor intensificado
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
WO2019239311A1 (en) * 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2020033876A1 (en) 2018-08-10 2020-02-13 Nantbio, Inc. Cellular adjuvants for viral infection
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗
WO2021067448A1 (en) * 2019-09-30 2021-04-08 Applied Genetic Technologies Corporation Adeno-associated virus (aav) systems for treatment of genetic hearing loss
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN113088538A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN114438128A (zh) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 一种增强型溶瘤腺病毒及其应用
US20240033334A1 (en) * 2020-12-04 2024-02-01 Gritstone Bio, Inc. Compositions and methods of use thereof
JP2024534178A (ja) * 2021-08-31 2024-09-18 ヴィア・バイオテクノロジー・インコーポレイテッド 結核ワクチン
CN118662620A (zh) * 2023-03-15 2024-09-20 康希诺生物股份公司 一种肺结核疫苗及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ319377A (en) 1995-09-01 2000-01-28 Corixa Corp polypeptides comprising a portion of a soluble M tuberculosis antigen
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
AU2001268678B2 (en) * 2000-06-20 2006-11-16 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2993042A1 (en) * 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
ES2442225T3 (es) 2004-04-28 2014-02-10 The Trustees Of The University Of Pennsylvania Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1
JP5164830B2 (ja) * 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
AU2006257323B2 (en) 2005-06-17 2011-12-22 Msd Italia S.R.L. Hepatitis C virus nucleic acid vaccine
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP3385387B1 (en) * 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
US8932600B2 (en) * 2010-01-27 2015-01-13 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
TR201902214T4 (tr) * 2010-04-16 2019-03-21 Glaxosmithkline Biologicals Sa Şempanze adenoviral vektörü-bazlı filovirüs aşıları.
PT3023106T (pt) * 2010-12-14 2019-11-04 Glaxosmithkline Biologicals Sa Composição antigénica de micobactéria
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
BE1024420B1 (fr) 2015-06-12 2018-02-19 Glaxosmithkline Biologicals Sa Polynucleotides et polypeptides d'adenovirus

Also Published As

Publication number Publication date
WO2017017050A1 (en) 2017-02-02
AR105470A1 (es) 2017-10-04
US20210060150A1 (en) 2021-03-04
AU2016301029B2 (en) 2019-08-22
CA2993371A1 (en) 2017-02-02
MX2018001215A (es) 2018-04-13
JP2018524393A (ja) 2018-08-30
MX2018001213A (es) 2018-04-13
US20180250375A1 (en) 2018-09-06
CN108135991A (zh) 2018-06-08
BR112018001683A2 (pt) 2018-09-18
BE1023915B1 (fr) 2018-01-31
AU2016301029A1 (en) 2018-02-01
GB201513176D0 (en) 2015-09-09
US20180216081A1 (en) 2018-08-02
BR112018001572A2 (pt) 2018-11-06
BE1023916A9 (fr) 2018-02-12
BE1023916B1 (fr) 2018-01-22
BE1023916A1 (fr) 2017-09-12
IL257071A (en) 2018-03-29
WO2017017049A1 (en) 2017-02-02
EP3328420A1 (en) 2018-06-06
CN108367061A (zh) 2018-08-03
BE1023915A9 (fr) 2018-01-24
EA201890355A1 (ru) 2018-08-31
CA2993277A1 (en) 2017-02-02
BE1023915A1 (fr) 2017-09-12
US20210386846A1 (en) 2021-12-16
EP3328421A1 (en) 2018-06-06
JP2018521666A (ja) 2018-08-09
US11110159B2 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
KR20180034589A (ko) 면역 반응을 유도하기 위한 신규한 방법
AU2019271972B2 (en) Adenovirus polynucleotides and polypeptides
AU2019204982B2 (en) Recombinant HCMV and RhCMV Vectors and Uses Thereof
AU2022203504B2 (en) Oncolytic tumor viruses and methods of use
KR101763093B1 (ko) 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
JP2024073576A (ja) 改変アデノウイルス
AU2017305176B2 (en) Compositions and methods of replication deficient adenoviral vectors for vaccine applications
KR101668163B1 (ko) Cmv용 백신으로서의 조건부 복제 시토메갈로바이러스
AU2018295421B2 (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR20230046313A (ko) 다중에피토프 백신 카세트
JP7698678B2 (ja) エプスタインバールウイルス抗原構築物
AU2017258857A1 (en) Subfamily E simian adenovirus A1309, A1321, A1325, A1295 and A1322 and uses thereof
KR20210090650A (ko) 알파바이러스 신생항원 벡터 및 인터페론 억제제
KR20210013589A (ko) 면역 체크포인트 억제제 공동-발현 벡터
KR20220041844A (ko) Hiv 항원 및 mhc 복합체
KR20230006825A (ko) 전염성 질병 항원 및 백신
KR20230014694A (ko) 항원-코딩 카세트
CN116940589A (zh) 重组sars-cov-2疫苗
DK2391638T3 (en) Abeadenovirus nucleic acid and amino acid sequences, vectors containing them, and uses thereof.
RU2800361C2 (ru) Стабильные составы цитомегаловируса
KR20230117163A (ko) 상동 아데노바이러스 백신접종

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination